Intra-muscular Botulinum Toxin A in Chronic Athletic Pubalgia
CompletedNCT05430893
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic athletic pubalgia is a frequent sport condition in which the effectiveness of medical treatment has not been proven. Intra-muscular injection of botulinum toxin A may have positive effects on pain in some chronic tendinitis. The investigators hypothesized that similar analgesic effect of intra-muscular botulinum toxin A may be observed in individuals with chronic AP. In the present study, the investigators aimed to describe the short-term evolution of pain and of activity limitations and quality of life, after an injection of the adductor longus with botulinum toxin A, in individuals with chronic AP, for whom medical and/or surgical treatments have failed.
Study details
- Official title
- Intra-muscular Botulinum Toxin A in Chronic Athletic Pubalgia: a Retrospective Observational Study
- Conditions
- Athletic Pubalgia
- Interventions
- Other: Botulinum Toxin A
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- Start date
- 2017-06-01
- Primary completion
- 2021-03-31
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- France
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * chronic AP * symptom duration ≥ 3 months * consistent clinical and magnetic resonance imaging findings according to the clinician * failure of medical and/or surgical treatments with persistent pain and inability to return to play * treatment with an intra-muscular injection of botulinum toxin A injection Exclusion Criteria: * age under 18 years * ongoing pregnancy or breastfeeding * treatments by anticoagulants * muscular disorder (e.g. polymyositis, myopathy or other neuromuscular conditions) * guardianship or curatorship * individuals who had received botulinum toxin type A treatment for less than one year
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05430893